多组学与机器学习可准确预测类风湿关节炎患者对阿达木单抗和依那西普的治疗反应
研究对80例类风湿关节炎患者在启动阿达木单抗或依那西普治疗前进行外周血单个核细胞、单核细胞和CD4+ T细胞的基因表达和/或DNA甲基化谱分析,6个月后按EULAR标准评估反应。研究发现两种药物反应者的转录特征存在差异,基于差异基因和差异甲基化位点的机器学习模型预测准确率分别达85.9%和79%以及84.7%和88%,随访研究验证了模型的高性能。
要点
- 阿达木单抗与依那西普反应者的转录特征在外周血单个核细胞中不同,并在单核细胞和CD4+ T细胞中重现。
- 基于差异基因的机器学习模型预测阿达木单抗和依那西普反应的总体准确率分别为85.9%和79%。
- 基于差异甲基化位点的模型预测阿达木单抗和依那西普反应的总体准确率分别为84.7%和88%。
核心结论
- 基于分子特征的机器学习模型可在阿达木单抗和依那西普治疗前准确预测类风湿关节炎患者的治疗反应。
研究设计与样本
- 研究纳入80例即将开始阿达木单抗或依那西普治疗的类风湿关节炎患者,治疗前采集外周血单个核细胞、单核细胞和CD4+ T细胞进行基因表达和/或DNA甲基化谱分析。
- 治疗6个月后根据欧洲抗风湿病联盟(EULAR)疾病反应标准评估治疗反应,并进行差异表达和甲基化分析以识别反应相关转录和表观遗传特征。
- 利用上述特征通过随机森林算法构建预测治疗前反应的机器学习模型,并通过随访研究进行验证。
主要发现
- 阿达木单抗和依那西普反应者的转录特征在外周血单个核细胞中不同,该现象在单核细胞和CD4+ T细胞中重现。
- 阿达木单抗反应者CD4+ T细胞中上调基因富集于TNF信号通路,而单核细胞中差异通路很少。
- 依那西普反应者的差异甲基化位点呈强高甲基化,而阿达木单抗反应者无此现象。
关键数值与推荐
- 基于差异基因的机器学习模型预测阿达木单抗和依那西普反应的总体准确率分别为85.9%和79%。
- 基于差异甲基化位点的机器学习模型预测阿达木单抗和依那西普反应的总体准确率分别为84.7%和88%。
- 随访研究验证了这些模型的高性能。
临床怎么用
- 基于分子特征的机器学习模型有望在启动抗TNF治疗前预测类风湿关节炎患者对阿达木单抗或依那西普的反应,推动个体化抗TNF治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To predict response to anti-tumor necrosis factor (anti-TNF) prior to treatment in patients with rheumatoid arthritis (RA), and to comprehensively understand the mechanism of how different RA patients respond differently to anti-TNF treatment. METHODS: Gene expression and/or DNA methylation profiling on peripheral blood mononuclear cells (PBMCs), monocytes, and CD4+ T cells obtained from 80 RA patients before they began either adalimumab (ADA) or etanercept (ETN) therapy was studied. After 6 months, treatment response was evaluated according to the European League Against Rheumatism criteria for disease response. Differential expression and methylation analyses were performed to identify the response-associated transcription and epigenetic signatures. Using these signatures, machine learning models were built by random forest algorithm to predict response prior to anti-TNF treatment, and were further validated by a follow-up study. RESULTS: Transcription signatures in ADA and ETN responders were divergent in PBMCs, and this phenomenon was reproduced in monocytes and CD4+ T cells. The genes up-regulated in CD4+ T cells from ADA responders were enriched in the TNF signaling pathway, while very few pathways were differential in monocytes. Differentially methylated positions (DMPs) were strongly hypermethylated in responders to ETN but not to ADA. The machine learning models for the prediction of response to ADA and ETN using differential genes reached an overall accuracy of 85.9% and 79%, respectively. The models using DMPs reached an overall accuracy of 84.7% and 88% for ADA and ETN, respectively. A follow-up study validated the high performance of these models. CONCLUSION: Our findings indicate that machine learning models based on molecular signatures accurately predict response before ADA and ETN treatment, paving the path toward personalized anti-TNF treatment.
引用
- Tao W, Concepcion AN, Vianen M, et al. Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 32909363. doi:10.1002/art.41516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。